Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Infectious Diseases Proposed As Focus Of Inter-Korea Health Cooperation

Executive Summary

Amid ongoing talks to denuclearize North Korea, the two Koreas are gearing up for bilateral cooperation in various industries including the health and medical sector, if and when international sanctions on the North are lifted. A new report suggests possible ways the two sides can initially work together in the area, with a focus on infectious diseases.

You may also be interested in...



Korea 2018 Review: Hopes And Worries Coexist In Pharma Sector

As the year end approaches, Scrip wraps up what major events made headlines in the South Korean pharma/biotech sector in 2018.

Historic Inter-Korean Summit Sparks Hopes Of Healthcare Exchanges

Following the signing of the Panmunjeom Declaration after their recent historic summit, North and South Korea are poised to resume economic cooperation, including projects in the healthcare sector, in line with an agreement the two sides reached in 2007. Although progress will likely depend on the upcoming summit between the US and North Korea and whether international sanctions are lifted, hopes over direct inter-Korean exchanges are brewing.

AI Healthcare, Medical Devices Shine In Korea Q1 Financings

After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS124403

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel